For more information regarding educational grant support opportunities for the Cardiometabolic Health Congress
please email info@cardiometabolichealth.org or call 877.571.4700.
The 2014 CMHC gratefully acknowledges the educational grant support provided by the following organizations:
Improving Awareness and Outcomes in Lipodystrophy Syndromes:
Clinical Manifestations, Diagnosis, and Evolving Therapeutic Strategies
Supported by an educational grant from AstraZeneca
Optimizing Antihypertensive Therapies in High-Risk and Difficult-to-Treat Patients with Hypertension
Supported by an educational grant from Forest Laboratories, Inc.
New Frontiers in Obesity Management: Advances in Neurobiological Treatment Strategies
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc
Triglyceride and Mixed Dyslipidemia Management: The Changing Landscape of CV Risk Reduction
Supported by an educational grant from AstraZeneca
Obesity Management 2014: New Perspectives and Therapeutic Options for a Growing Problem
Supported by an educational grant from Novo Nordisk, Inc.
Overcoming Obstacles in Obesity Management: New Tools, Techniques, and Treatment Strategies
Supported by an educational grant from Eisai, Inc.
Closing the Gaps in the Continuum of Care for Patients with Acute Coronary Syndromes: Implications for Optimal Antiplatelet Use
Supported by an educational grant from AstraZeneca
Novel and Emerging Combinations to Achieve Glycemic Control and Reduce Cardiometabolic Risk: A Focus on Incretin-Based Therapy and SGLT2 Inhibitors
Supported by an educational grant from AstraZeneca
The Triglycerides Conundrum: Practical Clinical Guidance for Reducing Residual CV Risk
Supported by an educational grant from Amarin Pharma, Inc.
Innovations in GLP-1 Receptor Agonist Therapy: Individualized Treatment Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes Mellitus
Supported by an educational grant from Lilly USA, LLC
Individualizing Therapy in Patients with Stable Ischemic Heart Disease: Managing the Full Spectrum of Comorbidities and Cardiometabolic Risk Factors
Supported by an educational grant from Gilead Sciences, Inc.
The Wide Spectrum of Familial Hypercholesterolemia: Discovering Your Highest Risk Patients and Optimizing Treatment
Supported by educational grants from Aegerion Pharmaceuticals, Inc. and Genzyme, A SANOFI COMPANY
Integrated Management of the Complexities of Cardiometabolic Diseases: A Patient-Centric Team Approach
Supported by an educational grant from Merck & Co., Inc.
Confronting Racial and Ethnic Disparities in Cardiometabolic Disease
Supported in part by educational grants from Arbor Pharmaceuticals and Merck & Co.
New Targets and Treatments for LDL Lowering: Role of PCSK9 Inhibitors
Supported by an educational grant from Amgen
Evolving Strategies for LDL-Lowering: Novel Targets and Treatments For CVD Risk Reduction
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals